Arterial ischemic stroke and cerebral venous thrombosis in children: a 12-year Argentinean registry.
Over a 12-year period, 112 consecutive children with arterial ischemic stroke (AIS) and 38 children with cerebral venous thrombosis (CVT) were prospectively recruited at a single pediatric center in Argentina. One or more underlying clinical conditions were identified in most patients (55%) with AIS and in almost all patients with CVT. Inherited and/or acquired prothrombotic disorders were detected in 17% of the patients with AIS and in 34% of the children with CVT. No associations between factor V Leiden or prothrombin G20210A mutation and children with AIS or CVT were found. Antithrombotic agents (i.e., aspirin, low-molecular-weight heparin and acenocoumarol) were administered without major hemorrhagic complications. In our cohorts, mortality due to the thrombotic episode was 1.8% in children with AIS. No child with CVT died from his or her thrombotic episodes. Three children (3.2%) and 1 adolescent (1.1%) with AIS had thrombotic progression and recurrence, respectively. A large percentage of children with AIS (68%) and CVT (32%) have had some kind of sequels that caused serious disability in approximately half the cases.
Servicio de Hematología-Oncología, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina. mbonduel@garrahan.gov.ar
Mariana
M
Bonduel
Gabriela
G
Sciuccati
Mirta
M
Hepner
Graciela
G
Pieroni
Aurora Feliú
AF
Torres
Juan Pablo
JP
Frontroth
Silvia
S
Tenembaum
D000293:Adolescent; D001118:Argentina; D002545:Brain Ischemia / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D005165:Factor V / Q000235:genetics; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007223:Infant; D020767:Intracranial Thrombosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D017354:Point Mutation; D012042:Registries; D012189:Retrospective Studies
D005343:Fibrinolytic Agents; C095381:factor V Leiden; D005165:Factor V